The RNA-binding protein HuR regulates the stability and translation of target mRNAs, while no HuR mutations have been found in cancer, a link between HuR and malignant transformation has been suggested in cancers of the breast, colon, lung and ovary.

HuR expression in non-small cell lung cancer correlates with vascular endothelial growth factor-C expression and lymph node metastasis

Cytoplasmic expression of HuR was identified as an independent prognostic factor for survival in non-small lung cell carcinoma.

Cytoplasmic HuR expression is associated with COX-2 expression in lung squamous cell carcinomas.

PTHrP mRNA is stabilized by HuR in human lung adenocarcinoma cells

Enhanced total HuR expression, as well as its cytoplasmic localization, was significantly associated with increased COX-2 expression in lung cancer.

Methyl(R217)HuR and MCM6 are inversely correlated and are prognostic markers in non small cell lung carcinoma

Reduction of miR-31 expression enhanced lung cancer proliferation and migration by repressing HuR expression

The present study shows the efficacy of silencing HuR in lung cancer cells using folate-conjugated nanoparticle system that is directed towards folate receptor-alpha overexpressing cancer cells.

HuR facilitated lung cancer stemness dependent on CDK3 expression. miR-873 or miR-125a-3p level was negatively correlated with HuR and CDK3 expression levels in lung cancer tissues. HuR facilitates lung cancer stemness via regulating miR-873/CDK3 and miR-125a-3p/CDK3 axis.

Computational analysis of publicly available microarray datasets of non-small cell lung cancer (NSCC) treated with EGFR targeted therapy identified ESR1 and ELAV1 as the most highly ranked hub genes involved in the NSCLC acquired TKI-resistance.

Negative expression of HuR and Bim correlates with lower EGFR-tyrosine kinase inhibitors sensitivity in tumor tissues obtained from EGFR-mutant nonsmall cell lung cancer patients.